Orally administrable modified-release pharmaceutical dosage form

US10905667B2 · kind B2 · utility

Assignees

• Bayer Pharma Aktiengesellschaft · DE
• BAYER HEALTHCARE LLC · DE

Inventors

• Anke Stroyer · Berlin, DE
• Carmen Lobback · Schöneiche, DE
• Peter Serno · Bensberg, DE
• Philipp Rubenbauer · Bensheim, DE
• Kai Lovis · Düsseldorf, DE
• Heiko Schirmer · Solingen, DE
• Danja Grossbach · Wuppertal, DE
• Donald Bierer · Daly City, US
• Britta Olenik · Bottrop, DE
• Tia Jacobs · Wuppertal, DE
• Julia Küsel · Bochum, DE

Key dates

• Filing date: Jul 24, 2018
• Grant date: Feb 2, 2021
• Expiry date: Jul 24, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.